# Austin Walne

> Austin Walne is a Series A investor at Artis Ventures backing Biotechnology and SaaS. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Artis Ventures](https://shizune.co/investors/profile/artis)
- Location: San Francisco, United States
- Total investments: 7
- Last investment: Jan 2026
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/walne
- X (Twitter): http://twitter.com/walne
- Website: http://www.av.co
- Facebook: https://www.facebook.com

Austin Walne is a Series A investor at Artis Ventures in San Francisco focused on Biotechnology and SaaS. Austin Walne is currently working at ARTIS Ventures, Second Front Systems, and Locus Biosciences.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 29% |
| SaaS | 1 | 14% |
| DevOps | 1 | 14% |
| Medical | 1 | 14% |
| Oncology | 1 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 43% |
| Seed | 1 | 14% |
| Series B | 1 | 14% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 29% |
| Ireland | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Luminate | Luminate is an oncology-focused healthtech and tech-enabled services company that partners with payers, providers, and people with cancer to reduce the cost of cancer care while improving quality of life and outcomes for patients. The company offers a portfolio of services and technologies that enable home-based cancer treatment, adverse eventmonitoring, and prevention of drug-induced side effects. | $21M | Series A | Jan 07, 2026 |  |
| Second Front Systems | Second Front Systems (2F) securely fast-tracks government access to software-as-a-service (SaaS) applications to help build a safer tomorrow. The 2F Suite is the only fully integrated platform that empowers you to build, secure, extend, and observe your software, and get it accredited for deployment in regulated environments with ease. With rootsin U.S. Government service, this public-benefit, venture-backed software company is trusted by Government agencies and leading software providers, to empower them to succeed in their contributions to global security. For more information, visit https://secondfront.com/. | $70M | Series C | Sep 13, 2024 |  |
| Luminate | Luminate is an oncology-focused healthtech and tech-enabled services company that partners with payers, providers, and people with cancer to reduce the cost of cancer care while improving quality of life and outcomes for patients. The company offers a portfolio of services and technologies that enable home-based cancer treatment, adverse eventmonitoring, and prevention of drug-induced side effects. | $15M | Series A | May 14, 2024 |  |
| Second Front Systems | Second Front Systems (2F) securely fast-tracks government access to software-as-a-service (SaaS) applications to help build a safer tomorrow. The 2F Suite is the only fully integrated platform that empowers you to build, secure, extend, and observe your software, and get it accredited for deployment in regulated environments with ease. With rootsin U.S. Government service, this public-benefit, venture-backed software company is trusted by Government agencies and leading software providers, to empower them to succeed in their contributions to global security. For more information, visit https://secondfront.com/. | $32M | Series A | Dec 07, 2022 |  |
| Locus Biosciences | Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment morequickly, resulting in a better medical outcome. | $35M | Series B | May 18, 2022 |  |
| Second Front Systems | Second Front Systems (2F) securely fast-tracks government access to software-as-a-service (SaaS) applications to help build a safer tomorrow. The 2F Suite is the only fully integrated platform that empowers you to build, secure, extend, and observe your software, and get it accredited for deployment in regulated environments with ease. With rootsin U.S. Government service, this public-benefit, venture-backed software company is trusted by Government agencies and leading software providers, to empower them to succeed in their contributions to global security. For more information, visit https://secondfront.com/. | $6M | Seed | Jul 07, 2020 |  |
| Locus Biosciences | Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment morequickly, resulting in a better medical outcome. | $19M | Series A | Nov 14, 2017 |  |

7 of 7 investments shown.

## Co-investors
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 3 deals together
- [Abstract](https://shizune.co/investors/profile/a-list-ventures) — VC Fund, 2 deals together
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund, 2 deals together
- [Gula Tech Adventures](https://shizune.co/investors/profile/gula-tech-adventures) — VC Fund, 2 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 2 deals together
- [Moore Strategic Ventures](https://shizune.co/investors/profile/moore-strategic-ventures) — VC Fund, 2 deals together

## About Artis Ventures

VC Fund · San Francisco, United States

ARTIS Ventures is a financial services firm that finances early-to-late-stage venture investments. The team supports its portfolio companies through their entire life cycle, from initial venture investment to public offering and beyond.

5 contacts available at Artis Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew McLean | Analyst | https://shizune.co/investors/profile/andrew-mclean-19c8 |
| Austin Walne | Partner | https://shizune.co/investors/profile/austin-walne |
| Henry Klingenstein | Partner | https://shizune.co/investors/profile/henry-klingenstein |
| Jeff Sheedy | Director of International Marketing | https://shizune.co/investors/profile/jeff-sheedy |
| Megan Daugherty | Director of Communications and Administration | https://shizune.co/investors/profile/megan-daugherty |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Austin Walne invest in?

Austin Walne invests primarily in Biotechnology, SaaS and DevOps startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Austin Walne last invest?

The most recent investment recorded for Austin Walne closed in Jan 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co